You are not logged in.

In vitro and in vivo assessment of docetaxel formulation developed for esophageal stents

Shaikh, Mohsin, Zhang, Huihui, Wang, Hongyuan, Guo, Xiuli, Song, Yunmei, Kanwar, Jagat Rakesh and Garg, Sanjay 2016, In vitro and in vivo assessment of docetaxel formulation developed for esophageal stents, American association of pharmaceutical scientists pharmscitech, In Press, pp. 1-8, doi: 10.1208/s12249-016-0501-7.

Attached Files
Name Description MIMEType Size Downloads

Title In vitro and in vivo assessment of docetaxel formulation developed for esophageal stents
Author(s) Shaikh, Mohsin
Zhang, Huihui
Wang, Hongyuan
Guo, Xiuli
Song, Yunmei
Kanwar, Jagat Rakesh
Garg, Sanjay
Journal name American association of pharmaceutical scientists pharmscitech
Season In Press
Start page 1
End page 8
Total pages 8
Publisher American Association of Pharmaceutical Scientists
Place of publication Berlin, Germany
Publication date 2016-02
ISSN 1530-9932
1530-9932
Keyword(s) docetaxel
drug-eluting stent
esophageal cancer
esophageal stent
self-expanding metal stents
Summary Esophageal cancer (EC) mostly affects the elderly population and is frequently diagnosed at an advanced stage. Self-expanding metal stents (SEMS) are the most popular mode of palliation, but they are associated with reocclusion caused by tumor growth. To overcome this problem, docetaxel (DTX)-loaded polyurethane formulations were prepared for stent application. The films were evaluated against the cancer cell lines, OE-19 and OE-21, and normal esophageal cell line Het-1A. The DTX and the formulations were evaluated in vitro for the cytotoxicity and in vivo in nude mice. It was found that DTX and the formulations have a weak activity against the EC cell lines and an even weaker activity against Het-1A cell line. Preliminary in vivo studies showed skin toxicity in nude mice necessitating modification of the formulation. Reevaluation in a mouse xenograft model resulted in toxicity at high dose formulations while the low dose formulation exhibited modest advantage over commercial IV formulation; however, there was no significant difference between the commercial IV and blank formulation. DTX combination with an anti-cancer agent having complementary mode of action and non-overlapping toxicity could yield better outcome in future.
Language eng
DOI 10.1208/s12249-016-0501-7
Field of Research 1115 Pharmacology And Pharmaceutical Sciences
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2106, American Association of Pharmaceutical Scientists
Persistent URL http://hdl.handle.net/10536/DRO/DU:30085921

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 18 Abstract Views, 4 File Downloads  -  Detailed Statistics
Created: Tue, 06 Sep 2016, 11:44:04 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.